Linkedin
RLS logo_header
Linkedin

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Biotherapeutics in Oncology

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said: “We are pleased to advance our collaboration with AstraZeneca to develop next-generation biotherapeutics in oncology. Harbour BioMed has collaborated with AstraZeneca on multiple programs since 2022, and over time, the two parties have established a trusted and solid partnership. With our strong capabilities enabled by our proprietary antibody platforms, we are well positioned to support AstraZeneca in developing innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally.”

Read the full story on "Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Biotherapeutics in Oncology"

Share:

More News

FDA Granted Fast Track Designation for TER-2013 for HR+ve/HER2neg Breast Cancer

“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”

FDA Clears amendment to Open U.S. Enrollment in Ongoing Ph 2 THIO-101 Trial Expansion

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two

ASCO 2026

Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.